Supplementary Figure 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma | Synapse
September 10, 2025Open Access
Supplementary Figure 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Key Points
A linear association exists between serum and stool succinate levels at apheresis.
This correlation may influence therapeutic outcomes for CAR-T therapy in myeloma patients.
Assessments included multiple myeloma patients undergoing CAR-T therapy and their metabolic profiles.
Understanding these relationships may enhance strategies for CAR-T therapy and improve patient responses.
Abstract
Supplementary Figure S8 illustrates the linear association between serum and stool succinate levels at the time of apheresis in multiple myeloma patients.